ClinicalTrials.gg
RecruitingNCT04550104CONCORDEUpdated Dec 19, 2025

A Platform Study of Novel Agents in Combination With Radiotherapy in NSCLC

A Phase 1 interventional study of Radiotherapy and Olaparib Oral Tablet [Lynparza] in Non Small Cell Lung Cancer, sponsored by University of Leeds. Recruiting at 14 sites in United Kingdom. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-12-19.

Sponsored by University of Leeds · Phase 1, Interventional, and Treatment

How we know · 11 judgments

From the registry’s dates

  • Primary completion was expected by Mar 2026, 8 months ago, but the record still lists the study as recruiting.
  • Started Mar 2021; still recruiting 5 years 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
200
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 11 studies testing olaparib in Carcinoma, Non-Small-Cell Lung — 2 open to participants now, 5 under way, 1 of them phase 3. olaparib · Carcinoma, Non-Small-Cell Lung.

Planned enrollment
5th of 11
200 · median 186
Started
2021
with 1 other
Phase 1
2 of 11
1 open now
Registered
8th of 11
by date
Lead sponsor
1 of 11
University of Leeds

Among the 11 studies testing olaparib in Carcinoma, Non-Small-Cell Lung, this one is the 5th largest by planned enrollment, is one of 2 that started in 2021, is one of 2 in phase 1, and was the 8th registered.

Carcinoma, Non-Small-Cell Lung

7,639 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

2 of the 11 studies testing olaparib in Carcinoma, Non-Small-Cell Lung are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About olaparib

olaparib: first FDA approval 2014 (LYNPARZA), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,324 Carcinoma, Non-Small-Cell Lung studies recruiting now, 987 (75%) set no upper age limit and 225 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies testing olaparib in Carcinoma, Non-Small-Cell Lung, or all of them as a file.
02

Study summary

CONCORDE is a multi-institution, multi-arm, Phase IB study that will determine the recommended phase II dose (RP2D) and safety profiles of different DNA damage repair inhibitors (DDRis) when given in an open label fashion in combination with fixed dose curative intent radiotherapy (RT) in patients with stage IIB/IIIA/IIIB NSCLC, followed by up to 12 months of consolidation durvalumab immunotherapy in selected study arms. The RP2D will be evaluated by incorporating the number of observed dose limiting toxicities (DLTs) into a time to event continuous reassessment method (TiTE- CRM) model within each of the experimental arms. TiTE-CRM is used here to take into account longer-term toxicities up to 13.5 months post start of radiotherapy and use these to inform dose escalation decision making.

Read the detailed description

Radiotherapy is an effective treatment for patients with non-small cell lung cancer (NSCLC) that has not spread beyond the chest area. Radiotherapy is used as a curative treatment but unfortunately for most patients the cancer can return. Radiotherapy kills cells by damaging their DNA. Cells have the ability to repair that damage, especially the cells of normal tissue. If DNA repair can be prevented radiotherapy should be more effective causing the cancer cells to die.

The study will use new drugs that affect how cells repair DNA damage, called DNA damage response inhibitors (DDRi). These will be given together with radiotherapy to hopefully improve the effectiveness of radiotherapy, followed by up to 12 months of durvalumab immunotherapy in selected study arms to develop the trial in line with the standard of care for NSCLC. The study will try to find out the most effective and safe dose of this combination treatment. This will be a clinical trial where patients due to have radiotherapy, with the hope of successful treatment that could lead to cure from their cancer or extension of life, will be offered entry onto the study. All patients will receive their radiotherapy, with 3 out of every 4 people also receiving a single DDRi drug alongside this. Both patients and study doctors will know prior to the start of the actual treatment whether a DDRi will be given, and if so which one; no placebos will be used. The patients will be followed closely to check for side effects and to assess how their cancer is responding to treatment. Blood samples will be taken to monitor treatment progress and to try to predict which patients are most likely to benefit from this type of combined treatment.

03

Conditions studied

  • Non Small Cell Lung Cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Core Inclusion Criteria (Radiation Phase)

  1. or cytologically confirmed NSCLC (patients where the local MDT agree the diagnosis is NSCLC after review of the available pathology and imaging at MDT can be enrolled after discussion with the CI).
  2. Not suitable for concurrent chemoradiotherapy/surgery due to tumour or patient factors
  3. Stage IIB and III (TNM 8th Edition).
  4. Planned to receive RT at curative intent doses (i.e., 60Gy) as part of treatment plan (either with or without induction chemotherapy).
  5. Patient considered suitable for radical RT by the local lung cancer multidisciplinary team and a clinical oncologist.
  6. If chemotherapy has been given previously, the maximum interval between the last day of chemotherapy and the start of RT \<10 weeks.
  7. Age ≥18
  8. estimated to be greater than 6 months.
  9. Performance status ≥70.
  10. MRC dyspnoea score \<3.
  11. (FEV1) ≥35% predicted and diffusing capacity of the lungs for carbon monoxide (DLCO or TLCO) ≥35% predicted.
  12. Patient must be fully informed about the study and have signed the form.
  13. Patient must be willing and able to comply with the protocol, have mental capacity and (if relevant) use effective throughout treatment and for 4 months for women of , and 6 months for men after treatment completion. Treatment is defined as including the last dose of durvalumab or DDRi in the consolidation phase.
  14. Adequate organ function as defined in master protocol.
  15. Patient has a body weight of >30kg.

Core Exclusion Criteria (Radiation Phase)

  1. Mixed non-small cell and small cell tumours.
  2. Confirmed progressive disease during induction chemotherapy.
  3. Participation in a study of an agent or using an investigational device within 4 weeks prior to the anticipated start of treatment.
  4. Current or previous malignant disease which may impact on a patient's estimated life expectancy (other than NSCLC).
  5. History of interstitial pneumonitis.
  6. Prior thoracic radiotherapy.
  7. Prior treatment with pneumotoxic drugs, e.g. busulfan, bleomycin, within the past year. If prior therapy in lifetime, then exclude if history of pulmonary toxicities from administration. Patients who have received treatment with nitrosoureas (e.g., carmustine, lomustine) in the year before study entry without experiencing lung toxicity are allowed on study.
  8. Mean resting interval (QTcF) >470 msec obtained from 3 .
  9. Received a prior autologous or allogeneic organ or tissue transplantation.
  10. Patients unable to swallow orally administered medications or chronic gastrointestinal (GI) disease likely to interfere with absorption of IMP in the opinion of the treating investigator (e.g. malabsorption syndrome, resection of the small bowel, poorly controlled inflammatory bowel disease etc.).
  11. Grade 2 or higher peripheral sensory neuropathy.
  12. Known positive test for , active or C infection.
  13. Positive pregnancy test (at eligibility assessment for women of childbearing potential) or breast-feeding women.
  14. Patients with persistent toxicities (> grade 2) caused by previous cancer therapy, excluding alopecia.
  15. Patients with myelodysplastic syndrome (MDS)/acute myeloid leukaemia (AML) or with features suggestive of MDS/AML.
  16. Major surgery within 2 weeks of confirmation of eligibility.
  17. Patients considered a poor medical risk by the investigator due to a serious, uncontrolled medical disorder, non-malignant system disease or active uncontrolled infection. Examples include, but are not limited to, uncontrolled ventricular arrhythmia, uncontrolled hypertension, uncontrolled atrial fibrillation, active bleeding, recent (within 3 months) myocardial infarction, major seizure, active COVID-19, any psychiatric disorder that prohibits obtaining informed consent.
  18. Active or prior documented or inflammatory disorders (including inflammatory bowel disease (e.g., ulcerative colitis or Crohn's disease), systemic lupus erythematosus, Sarcoidosis syndrome, or Wegener syndrome (granulomatosis with polyangiitis, Graves' disease, rheumatoid arthritis, hypophysitis, uveitis, etc.
  19. Exclusions as described in the relevant study arm protocol. Patients ineligible for a particular study arm may be considered for entry into an alternative study arm if an appropriate slot is available and they meet all the inclusion and exclusion criteria for that arm. This will need to be discussed with CTRU and the patient will be required to reconsent using the appropriate study arm PIS/ICF.

Core Inclusion Criteria (Consolidation Phase)

  1. A minimum of 4 and a maximum of 8 weeks* have elapsed following completion of RT
  2. Any toxicities from RT have resolved to grade 1. If patient has pneumonitis following RT treatment, this must be asymptomatic (grade 1). If pneumonitis is ≥2 or requiring , then participant is not eligible
  3. Karnofsky Performance status ≥70
  4. The laboratory requirements set out in Table 1 of the master protocol are met
  5. Patient has no known to the of durvalumab
  6. Patient has body weight of >30kg *Investigators should ideally aim to start consolidation treatment within 6 weeks, following the receipt of the CT scan results to rule out progression.

Core Exclusion Criteria (Consolidation Phase)

  1. Progressive disease during RT or at the end of RT treatment response assessment.
  2. Participant declines treatment in the consolidation phase.
  3. Patients who have received prior or anti PD-L1 treatment.
  4. Major surgery within 4 weeks of confirmation of eligibility for consolidation phase.
  5. Current or prior use of medication within 14 days before the first dose of durvalumab.
  6. Patients considered a poor medical risk by the investigator due to a serious, uncontrolled medical disorder, non-malignant system disease, active GI infection or active uncontrolled infection.
  7. Active or prior documented autoimmune or inflammatory disorders (including inflammatory bowel disease e.g., colitis or Crohn's disease), systemic lupus erythematosus, Sarcoidosis syndrome, or Wegener syndrome granulomatosis with polyangiitis, Graves' disease, rheumatoid arthritis, hypophysitis, uveitis, etc).
Terms in these criteria, in plain language(19)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
200 participants (estimated)

Study arms

  • Active comparator
    Radiotherapy only

    Radiation: Radiotherapy

  • Experimental
    Olaparib + radiotherapy

    Radiation: Radiotherapy · Drug: Olaparib Oral Tablet [Lynparza]

  • Experimental
    AZD1390 + radiotherapy

    Radiation: Radiotherapy · Drug: AZD1390

  • Experimental
    Ceralasertib (AZD6738) + radiotherapy + Consolidation durvalumab

    This study arm will include up to 12 months of consolidation durvalumab for eligible participants following the completion of radiotherapy +/- DDRi.

    Radiation: Radiotherapy · Drug: Ceralasertib · Drug: Durvalumab

  • Experimental
    AZD5305 + radiotherapy + Consolidation durvalumab

    This study arm will include up to 12 months of consolidation durvalumab for eligible participants following the completion of radiotherapy +/- DDRi.

    Radiation: Radiotherapy · Drug: AZD5305 · Drug: Durvalumab

  • Active comparator
    RT + consolidation durvalumab

    Radiation: Radiotherapy · Drug: Durvalumab

  • Experimental
    Arm D - did not proceed

    Arm D - did not proceed

    Radiation: Radiotherapy

Interventions

  • RadiationRadiotherapy

    Administered as 30 fractions of 2Gy. Total 60 60Gy. Administered once daily monday to friday.

  • DrugOlaparibStudies of OlaparibOlaparib pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Oral tablet

    Also known as: AZD2281

  • Oral tablet

  • Oral Tablet

    Also known as: AZD6738

  • Oral Tablet

  • 1500mg iv infusion

06

What researchers measure

Primary outcomes

  1. Dose limiting Toxicities

    Dose-limiting toxicities (DLTs), within 13.5 months of starting radiotherapy, in order to establish the Recommended Phase II Dose (RP2D) of each DDRi-RT combination.

    Time frame: 13.5 months after start of radiotherapy

Secondary outcomes

  1. Safety and toxicity

    Safety will be reported based on the occurrence of SAEs, SARs and SUSARs. Toxicity will be reported based on adverse events, as graded by CTCAE V5.0, and determined by routine clinical assessments at each centre.

    Time frame: 2 years after end of RT

  2. Treatment compliance

    Treatment compliance will be measured by overall radiotherapy treatment time and delays, omissions and reductions to treatment doses (both DDRi and RT).

    Time frame: End of trial treatment (DDRi and RT)

  3. Best overall response

    Best overall response will be measured as the best response (complete response, partial response or stable disease) recorded until disease progression, reported up to 2 years post-RT. This will be assessed using RECIST 1.1

    Time frame: 2 years after end of RT

  4. Disease control

    This will be assessed using the Green Criteria. Disease Control includes either the complete disappearance of all evidence of malignant disease or residual radiographic abnormalities assessed by chest CT scan at 3 and 6 months after completion of RT, which then remains stable for an additional 6 months or more and which then qualifies as controlled local disease.

    Time frame: 2 years after end of RT

  5. Progression-free survival

    Participants who have not progressed at the time of analysis will be censored at the last date they were known to be alive and progression free

    Time frame: 2 years post-RT

  6. Overall survival

    Participants who have not died at the time of analysis will be censored at the last date they were known to be alive

    Time frame: 2 years post-RT

  7. Changes in Health Related Quality of Life

    Health Related Quality of Life will be determined using EORTC QLQ-C30, IL-73 and IL-74

    Time frame: 2 years after end of RT

  8. Objective response rate

    Objective response rate (ORR) is defined as the proportion of patients who have a partial or complete response to therapy. The proportion of patients with evaluable scans that achieve at least a partial response, as defined by RECIST v1.1(31), will be presented with 95% confidence intervals.

    Time frame: 2 years after end of RT

  9. Changes in tumour size during and following treatment with DDRi-RT compared to RT alone.

    Time frame: 2 years after end of RT

Other outcomes

  1. Assessment of mutations in components of DDR pathway in archival tumour and cfDNA prior to therapy

    Exploratory endpoint

    Time frame: 2 years after end of RT

  2. Assessment of T cells within the archival tumour specimens

    Exploratory endpoint

    Time frame: 2 years after end of RT

  3. Changes in cfDNA during and following treatment with DDRi-RT compared to RT alone.

    Exploratory endpoint

    Time frame: 2 years after end of RT

  4. Changes in circulating biomarkers of cardiac and respiratory toxicity during and following treatment with DDRi-RT compared to RT alone.

    Exploratory endpoint

    Time frame: 3 months post end of RT

  5. Changes in circulating peripheral T cell sub-sets during and following treatment with DDRi-RT compared to RT alone.

    Exploratory endpoint

    Time frame: 2 years after end of RT

  6. Changes in lung parenchyma during and following treatment with DDRi-RT compared to RT alone.

    Exploratory endpoint

    Time frame: 2 years after end of RT

07

Study locations

14 of 14 sites recruiting
08

References and documents

Publications

  • Faivre-Finn C, Brown S, Ryan A, Greystoke A; CONCORDE Investigators. The UK at the Forefront of Innovative Drug-Radiotherapy Combination Clinical Trials: Introducing the CONCORDE Platform. Clin Oncol (R Coll Radiol). 2020 Jun;32(6):358-362. doi: 10.1016/j.clon.2020.02.003. Epub 2020 Feb 24. No abstract available. PubMed 32107107 ↗
  • Walls GM, Oughton JB, Chalmers AJ, Brown S, Collinson F, Forster MD, Franks KN, Gilbert A, Hanna GG, Hannaway N, Harrow S, Haswell T, Hiley CT, Hinsley S, Krebs M, Murden G, Phillip R, Ryan AJ, Salem A, Sebag-Montefoire D, Shaw P, Twelves CJ, Walker K, Young RJ, Faivre-Finn C, Greystoke A. CONCORDE: A phase I platform study of novel agents in combination with conventional radiotherapy in non-small-cell lung cancer. Clin Transl Radiat Oncol. 2020 Sep 22;25:61-66. doi: 10.1016/j.ctro.2020.09.006. eCollection 2020 Nov. PubMed 33072895 ↗
  • Walker K, Hinsley S, Phillip R, Oughton JB, Murden G, Chalmers AJ, Faivre-Finn C, Greystoke A, Brown SR; CONCORDE Investigators. Implementation of the Time-to-Event Continuous Reassessment Method Design in a Phase I Platform Trial Testing Novel Radiotherapy-Drug Combinations-CONCORDE. JCO Precis Oncol. 2022 Nov;6:e2200133. doi: 10.1200/PO.22.00133. PubMed 36446040 ↗

Individual participant data

Plan to share: Yes — De-identified individual participant data datasets generated and/or analysed during the current study will be available upon request from the Clinical Trials Research Unit, University of Leeds. Data will be made available at the end of the trial. Data will remain available from then on for as long as CTRU retains the data. CTRU makes data available by a 'controlled access' approach. Data will only be released for legitimate secondary research purposes, where the Chief Investigator, Sponsor and CTRU agree that the proposed use has scientific value and will be carried out to a high standard (in terms of scientific rigour and information governance and security), and that there are resources available to satisfy the request. Data will only be released in line with participants' consent, all applicable laws relating to data protection and confidentiality, and any contractual obligations to which the CTRU is subject.

Time frame: At the end of the trial, i.e. usually when all primary and secondary endpoints have been met and all key analyses are complete.

Access criteria: Contact CTRU-DataAccess@leeds.ac.uk in the first instance. No individual participant data will be released before an appropriate agreement is in place setting out the conditions of release. The agreement will govern data retention, usually stipulating that data recipients must delete their copy of the released data at the end of the planned project. The CTRU encourages a collaborative approach to data sharing, and believe it is best practice for researchers who generated datasets to be involved in subsequent uses of those datasets. Recipients of trial data for secondary research will also receive data dictionaries, copies of key trial documents and any other information required to understand and reuse the released datasets. The conditions of release for aggregate data may differ from those applying to individual participant data. Requests for aggregate data should also be sent to the above email address to discuss and agree suitable requirements for release.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2021 (actual). Primary completion is estimated for Mar 2026, 60 months after the start.

Of 225 non-industry phase 1 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 54 months of starting (the median), counting those still running; a quarter within 36 and three quarters within 80. This study's planned 60 months is above that.

Counting every sponsor, half of 699 studies reached it within 50 months; a quarter within 31 and three quarters within 70.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 24, 2020
First posted
Sep 16, 2020
StartActual
Mar 17, 2021
Primary completionEst.
Mar 2026
CompletionEst.
Mar 2028
Last update
Dec 19, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 19, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04550104
Collaborators
University of Manchester, Newcastle University, University of Oxford, The Leeds Teaching Hospitals NHS Trust, Beatson West of Scotland Cancer Centre, University of Glasgow, Velindre NHS Trust, University College London Hospitals, Queen's University, Belfast, University of Sheffield
Responsible party
Sponsor
First posted
Sep 16, 2020
Start date
Mar 17, 2021
Primary completion
Mar 2026 (estimated)
Completion
Mar 2028 (estimated)
Last update
Dec 19, 2025

Study contacts

Jamie B Oughton, MPhil
Contact
CTRU_CONCORDE@Leeds.ac.uk
0113 343 1494
Alastair Greystoke, MB ChB, MSc, PhD
principal investigator · Newcastle University
Corinne Faivre-Finn, MD, PhD
principal investigator · University of Manchester

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Olaparib · AZD1390 · Ceralasertib · AZD5305

Start the discussion